Informed Consent Form Template Research

HUMAN RESEARCH PARTICIPANT INFORMED CONSENT AND AUTHORIZATION AGREEMENT

DOCUMENT CONTROL

• Effective Date: [Effective Date]
• Document Version: 3.4-PROD
• Jurisdiction / Governing Law: [State/Country, e.g., State of Delaware, United States]
• Protocol ID / Project Title: [Protocol ID Number and Full Study Title]

---

1. OFFICIAL NOTICE & LEGAL DISCLAIMER

LEGAL NOTICE: This document is an enterprise-grade legal and operational template designed for human subject research. It establishes the contractual, ethical, and regulatory parameters governing the collection, processing, and utilization of participant data and biological/physical samples. Modification of this template without prior review by qualified legal counsel specialized in human research protections (e.g., HIPAA, GDPR, Common Rule 45 CFR 46) may result in severe regulatory non-compliance, civil liability, and institutional review board (IRB) sanction.

---

2. PARTIES & DEFINITIONS

This Informed Consent and Authorization Agreement ("Agreement") is entered into by and between:

• Research Institution / Sponsor: [Legal Name of Company/Institution], having its principal place of business at [Physical Address] (hereinafter referred to as the "Sponsor"), and
• Research Participant: [Participant Full Legal Name], residing at [Participant Residential Address] (hereinafter referred to as the "Participant").

Definitions:

1. "Study": The specific research protocol titled [Full Study Title], designed to investigate [Briefly state the core objective of the research].
2. "Data": All personally identifiable information (PII), protected health information (PHI), behavioral metrics, telemetry, digital logs, and analytical outputs derived from the Participant during the course of the Study.
3. "Biological Materials": Any biological samples, tissue, blood, DNA, RNA, or cellular derivatives collected from the Participant pursuant to this Study.
4. "Investigator": [Principal Investigator Name], the lead researcher responsible for the execution of the Study protocol.

---

3. OPERATIVE CLAUSES & TERMS

Section 1: Purpose and Voluntary Participation

1.1 The Participant acknowledges that they have been invited to participate in the Study. Participation is entirely voluntary. 1.2 The Participant may refuse to participate or may withdraw from the Study at any time, without penalty, loss of benefits, or adverse impact on their medical care, employment, or legal standing, by submitting a written notice of withdrawal to the Investigator.

Section 2: Study Procedures and Duration

2.1 The Participant agrees to undergo the procedures outlined in the Study protocol, which include: [Itemize procedures, e.g., completion of periodic surveys, physical examinations, blood draws, digital tracking]. 2.2 The total expected duration of the Participant's involvement in the Study is [Number of days/weeks/months], involving approximately [Number] visits or digital touchpoints, each lasting roughly [Duration in minutes/hours].

Section 3: Risks, Discomforts, and Inconveniences

3.1 The Participant acknowledges that participation in the Study may involve foreseeable risks, discomforts, and inconveniences, including but not limited to: [List specific physical, psychological, economic, or privacy risks, e.g., bruising from blood draws, breach of confidentiality, emotional fatigue]. 3.2 The Sponsor and Investigator will employ industry-standard administrative, physical, and technical safeguards to mitigate the risk of data breaches or physical harm.

Section 4: Potential Benefits

4.1 The Participant acknowledges that they may not receive direct medical or commercial benefit from participating in this Study. 4.2 The primary value of the Study is the contribution of generalized scientific knowledge to the fields of [Specify Field, e.g., oncology, human-computer interaction, pharmacokinetics].

Section 5: Confidentiality, Data Protection, and HIPAA/GDPR Authorization

5.1 By executing this Agreement, the Participant authorizes the Sponsor, the Investigator, and their designated agents to collect, use, store, analyze, and transfer their Data and Biological Materials. 5.2 All Data will be pseudonymized (coded with a unique identifier) wherever feasible. Research records will be kept in locked filing cabinets or encrypted digital repositories accessible only to authorized study personnel. 5.3 To the extent required by applicable law (including the Health Insurance Portability and Accountability Act [HIPAA] and the General Data Protection Regulation [GDPR]), this authorization shall remain valid until [Expiration Date or "the conclusion of the research study and its post-market surveillance"]. 5.4 The Participant retains the right to access, rectify, or request the deletion of their personal data, subject to limitations necessary to preserve the integrity of the research findings.

Section 6: Compensation and Costs

6.1 The Participant [will / will not] receive financial compensation for their time and travel expenses associated with the Study. 6.2 If compensation is applicable, the Participant shall receive [$Amount] per [milestone/completed visit], up to a maximum aggregate amount of [$Total Amount]. 6.3 The Participant or their insurance will not be billed for any procedures, tests, or investigational products explicitly mandated by the Study protocol.

Section 7: Commercialization and Intellectual Property Rights

7.1 The Participant explicitly relinquishes any claim to commercial, intellectual property, or patent rights arising from discoveries, inventions, commercial products, or data analytics developed by the Sponsor or its collaborators using the Data or Biological Materials collected under this Agreement. 7.2 Biological Materials may be stored in institutional biorepositories indefinitely and utilized for future biomedical research, subject to independent ethical review board approval.

Section 8: Injury Liability and Emergency Medical Treatment

8.1 In the event of physical injury resulting directly from research procedures, immediate emergency medical treatment will be made available through [Name of Medical Facility/Hospital]. 8.2 Neither the Sponsor nor the Investigator provides monetary compensation or free long-term medical care for research-related injuries unless required by mandatory local law. Signing this form does not waive any legal rights the Participant may have to seek compensation through the courts for negligence.

Section 9: Contacts and Questions

9.1 For questions regarding the Study, research-related injuries, or to withdraw from participation, the Participant shall contact the Principal Investigator, [Principal Investigator Name], at [Phone Number] or [Email Address]. 9.2 For questions regarding Participant rights, ethical concerns, or complaints, contact the Institutional Review Board (IRB) / Ethics Committee at [IRB Phone Number] or [IRB Email Address].

---

4. SIGNATURES & ACKNOWLEDGMENT BLOCK

By signing below, the Participant (or the Participant's legally authorized representative) acknowledges that they have read and understood this entire Informed Consent and Authorization Agreement, that all questions have been answered to their satisfaction, and that they voluntarily agree to participate in the Study under the terms stipulated herein.

PARTICIPANT / LEGAL REPRESENTATIVE:

• Printed Name: [Participant Full Legal Name]
• Title (if signing on behalf of Participant): [e.g., Parent, Legal Guardian, Power of Attorney]
• Signature: ____________________________________________________
• Date: [DD / MM / YYYY]

---

PERSON OBTAINING CONSENT:

I certify that I have accurately explained the nature, purpose, potential risks, and benefits of this Study to the Participant, and that they have been given the opportunity to ask questions.

• Printed Name of Investigator/Designee: [Investigator Full Name]
• Title/Role: [e.g., Principal Investigator, Clinical Research Coordinator]
• Signature: ____________________________________________________
• Date: [DD / MM / YYYY]

---

5. STEP-BY-STEP EXECUTION GUIDE

1. Customization & Review: Populate all bracketed fields ([...]) with precise project parameters. Have the draft reviewed by your institutional legal counsel and approved by the relevant Institutional Review Board (IRB) or Ethics Committee prior to deployment.
2. Pre-Consent Briefing: Ensure the Investigator or authorized clinical coordinator conducts a verbal briefing with the Participant, walking them through the risks, benefits, and data usage policies before requesting a signature.
3. Execution & Counter-Signing: Collect wet-ink signatures or legally compliant electronic signatures (e.g., compliant with 21 CFR Part 11 or eIDAS) from both the Participant and the authorized study representative on the same date.
4. Archival & Distribution: Provide a fully executed copy of this Agreement to the Participant for their records. Retain the master signed copy in the Investigator’s Trial Master File (TMF) or Regulatory Binder for the statutory retention period (typically a minimum of 7 years post-study completion).